Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretrovial therapy

HIV Clinical Trials

Volumn 13, Issue 6, 2012, Pages 350-356

  Bech, Anneke ^a   Van Bentum, Petra ^a   Telting, Darryl ^a   Gisolf, Jet ^a   Richter, Clemens ^a   De Boer, Hans ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

bone mineral disease; HIV; tenofovir; vitamin D deficiency

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; LAMIVUDINE; PARATHYROID HORMONE; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATE; POTASSIUM; TENOFOVIR; VIRUS RNA; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CALCIUM BALANCE; CALCIUM DEFICIENCY; CALCIUM INTAKE; CALCIUM METABOLISM; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEMUR NECK; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE ABSORPTION; LUMBAR SPINE; MALE; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PILOT STUDY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; TREATMENT DURATION; URINARY EXCRETION; URINE PH; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADENINE; ADULT; ANTI-HIV AGENTS; BONE DENSITY; CALCIUM; FIBROBLAST GROWTH FACTORS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; PHOSPHATES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84870595909     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1306-350     Document Type: Article

References (21)

1. Buchacz K, Brooks JT, Tong T, et al. Evaluation of hypophosphatemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected outpatients receiving highly active antiretroviral therapy. HIV Med. 2006;7:451-456 (Pubitemid 44269812)
2. Badiou S, De Boever CM, Terrier N, et al. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? J Infect. 2006;52(5):335-358
3. Bech A, Bentum van P, Nabbe K, et al. Fibroblast growth factor 23 in hypophosphatemic HIV-positive adults on tenofovir [published online ahead of print March 30, 2012]. HIV Med
4. Paccou J, Viget N, Legrout-Gerot I, et al. Bone loss in patients with HIV infection. Joint Bone Spine. 2009;76(6):637-641
5. Mc Comsey G. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. HIV/AIDS. 2010;51:937-946
6. Madeddu G, Solinas P, Calia GM, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. J Nucl Med Mol Imaging. 2004;48:39-48 (Pubitemid 39069663)
7. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D defi ciency and increased alkaline phosphatase. AIDS. 2010:24;1923-1928
8. Mueller N, Fux C, Ledergerber B et al. High prevalence of severe vitamin D defi ciency in combined antiretroviral therapy-naive and successfully treated Swiss patients. AIDS. 2010:24;1127-1134
9. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773-780
10. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the fi rst 4 years. AIDS. 2007;21:1273-1281 (Pubitemid 46883481)
11. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a metaanalytic review. AIDS. 2006;20(17):2165-2174 (Pubitemid 44684707)
12. Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis. 2010;23(1):1-8
13. Grigsby IF, Pham L, Mansky LM, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun. 2010;394:48-53
14. Fux CA, Rauch A, Simcock M et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 2008;13(8):1077-1082
15. Childs KE, Fishman SL, Constable C, et al. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26(8):855-859
16. Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes. 2010;17(6):523-529
17. Briot K, Kolta S, Flandre P, et al. Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies. Bone. 2011;48(5):1133-1199
18. Hansen AB, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med. 2011;12(3):157-165
19. van Groningen L, Opdenoordt S, van Sorge A, et al. Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J Endocrinol. 2010;162: 805-811
20. Bijvoet OL. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin Sci. 1969;37:23-36
21. Kemperman FA, Krediet RT, Arisz L. Formula-derived prediction of the glomerular filtration rate from plasma creatinine concentration. Nephron. 2002;91:547-558. (Pubitemid 34914052)